Amid deep cuts to U.S. government-funded research and revived scrutiny of their work, Chinese and Chinese-American researchers are reassessing their futures in this country, potentially shifting the balance in global scientific innovation, as well as in the biopharma industry.

The Trump administration’s vast overhaul of the U.S. scientific enterprise has impacted researchers of all stripes. But, at least among scientists funded by the National Institutes of Health, Chinese and Chinese-American researchers, in particular, face a particularly big impact, given their heavy representation in the field.

For decades, with comparatively fewer opportunities in China, scientists from there have sought to advance their careers in the United States. Now, China is providing more such opportunities and making rapid scientific advances of its own. At the same time, opportunities in the United States seem to be shrinking.